{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'of attributability, and any laboratory abnormalities that are considered to be AEs or', 'potentially harmful to the participant, at the last on-study visit.', 'Participants are not obligated to state the reason for withdrawal. However, a reason for', 'withdrawal must be documented by the Investigator on the Completion/Withdrawal', 'section of the electronic case report form (eCRF). Every effort should be made by the', 'Investigator to follow-up participants who withdraw from the study.', '7.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible, 3', \"telephone calls and, if necessary, a certified letter to the participant's last known\", 'mailing address or local equivalent methods). These contact attempts should be', \"documented in the participant's medical record.\", 'Should the participant continue to be unreachable, he/she will be considered to', 'have withdrawn from the study with a primary reason of lost to follow-up.', '56']['2017N331008_06', 'CONFIDENTIAL', '208090', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the Schedule of Activities', '(SoA) (Section 1.3).', 'Please refer to Appendix 14 in Section 11.14 for study management information', 'during the COVID-19 pandemic.', 'Protocol waivers or exemptions are not allowed', 'Immediate safety concerns should be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study intervention.', 'Adherence to the study design requirements, including those specified in the SoA,', 'is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain', 'a', 'screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', \"Procedures conducted as part of the participant's routine clinical management\", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-specified', 'criteria and was performed within the time frame defined in the SoA.', 'Screening Assessments', 'Written informed consent must be obtained from each potentially eligible participant by', 'study site personnel prior to the initiation of any Screening procedures as outlined in this', 'protocol. The consent form must have been approved by the IRB/Independent Ethics', 'Committee (IEC). After signing an informed consent, participants will complete', 'Screening assessments to determine participant eligibility. Each participant being', 'screened for enrolment evaluation will be assigned a participant number at the Screening', 'visit. This number will be given sequentially in chronological order of participant', 'presentation according to a numeric roster provided by PPD.', 'Eligibility criteria must be assessed carefully at the Screening visit. Physical', 'examinations should be conducted as part of normal routine clinical care but will not be', 'collected systematically in the eCRF. Cardiovascular medical history/risk factors,', 'including vital signs (as detailed in the eCRF) will be assessed at the Screening visit and', 'assessments will include height, weight, blood pressure, smoking status and history,', 'pertinent medical conditions (e.g., hypertension, diabetes mellitus), and family history of', 'premature cardiovascular disease. Background information to be collected at Screening', 'includes demography (year of birth, sex, race and ethnicity), prior ART history, medical', 'history and current medical conditions, menopause history, concomitant medications,', 'assessment of CDC HIV-1 classification, a 12-lead ECG and laboratory assessments as', 'detailed in Section 1.3.', 'Eligible participants may be randomly assigned immediately as soon as all Screening', 'assessments are complete and the results are available and documented. All participants', '57']['2017N331008_06', 'CONFIDENTIAL', '208090', 'will complete the Screening period up to 28 days prior to Baseline (Day 1) during which', 'all clinical and laboratory assessments of eligibility must be performed and reviewed.', 'The Screening period of up to 28 days is to accommodate availability of all Screening', 'assessment results, completion of source document verification to satisfy the Inclusion', 'and Exclusion Criteria including the required previous HIV-1 RNA values, and', 'scheduling. All Screening results must be available prior to randomization.', \"All information about the participant's current and any past regimen must be\", 'available for review by the Principal Investigator or designee prior to', 'randomization. Source documents from other medical facilities must be', 'located/received during the 28-day screening period and under no circumstances', 'may the participant be randomized in the absence of source documentation, even if', 'there are delays in receipt of this information. A participant may be re-screened if', 'the source documentation is obtained after the screening window closes.', 'Details regarding prior resistance data must be noted in the source documentation.', 'Resistance testing reports with genotypic data must be provided to ViiV after screening', 'and before randomization for review by ViiV. Sites must wait for the study virologists to', 'confirm the lack of exclusionary resistance mutations, which will be provided to the site', 'before the screening window closes. Details for tracking historic resistance report', 'availability and sending to ViiV Virology for evaluation are described in the SRM.', 'Details regarding baseline or prior resistance data must be noted in the source', 'documentation. If a participant is identified as having been mistakenly', 'screened/randomized with exclusionary resistance, they will be withdrawn.', 'Participants with chronic active hepatitis B virus infection are excluded. Evidence of', 'Hepatitis B virus (HBV) infection is based on the results of testing at Screening for', 'Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B', 'surface antibody (anti-HBs), and HBV DNA. HBV DNA testing will only be performed', 'for participants with positive anti-HBc and negative HBsAg and negative anti-HBs (past', 'and/or current evidence).', 'All participants will be screened for syphilis at screening. Participants with untreated', 'syphilis infection, defined as a positive Rapid Plasma Reagin (RPR) without clear', 'documentation of treatment, are excluded unless they complete treatment during the', '28-day screening window and 7 days prior to randomization. Participants who complete', 'treatment after the screening window closes may be rescreened.', 'Participants who meet all entry criteria are randomized and assigned a randomization', 'number. Participants not meeting all inclusion and exclusion criteria at initial screen may', 'be rescreened and receive a new participant number one time unless they were excluded', 'for reason of having exclusionary historic genotypic resistance or for a viral load', '>50c/mL at time of screening. Participants who are randomized into the trial and', 'subsequently withdrawn from the study for any reason may not be rescreened.', '58']\n\n###\n\n", "completion": "END"}